U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07015190) titled 'Neoadjuvant Darovasertib in Primary Uveal Melanoma' on June 03.
Brief Summary: This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma
Study Start Date: Sept. 30, 2025
Study Type: INTERVENTIONAL
Condition:
Uveal Melanoma
Intervention:
DRUG: Darovasertib
Dosed orally, twice daily (28-day/ cycle
PROCEDURE: Primary Local Therapy
Plaque Brachytherapy or Enucleation
Recruitment Status: NOT_YET_RECRUITING
Sponsor: IDEAYA Biosciences
Published by HT Digital Content Services with permission from Health Daily Digest....